Surrozen Q1 2026 net loss $127.5M; cash $106.9M; on track for SZN-8141 IND in H2 2026

Surrozen, Inc./DE

2026-Q1 EPS reported -$11.65 revenue$5,000,000

Net loss $127.5M ($11.65/sh) vs $27.0M ($7.43/sh) in Q1 2025, driven by non-cash fair value changes on warrants and tranche liability.
Cash and equivalents $106.9M as of Mar 31, 2026, up from $89.2M at Dec 31, 2025.
Received $5M milestone payment from Boehringer Ingelheim in April 2026 for SZN-413 GLP toxicology study progress.
On track to submit IND for SZN-8141 for retinal diseases in H2 2026; preclinical data presented at ARVO.
R&D expenses $9.3M (up $2.7M YoY) due to ophthalmology program costs; G&A $6.1M (up $2.1M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surrozen, Inc./DE reported the quarter ended March 31, 2026 results: net income $127.5 million, EPS ($11.65) per share.

Period: the quarter ended March 31, 2026
Net income: $127.5 million
EPS: ($11.65) per share
Result: reported results

Exact text from the filing

Net loss was $127.5 million, or ($11.65) per share for the quarter ended March 31, 2026

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0001193125-26-208999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.